Trial Profile
An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Brivaracetam (Primary)
- Indications Epilepsy
- Focus Registrational; Therapeutic Use
- Sponsors UCB Pharma SA
- 05 Dec 2017 Results of pooled analysis from two phase II, six phase III and associated long-term follow-up studies presented at the 71st Annual Meeting of the American Epilepsy Society.
- 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.
- 01 Nov 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.